Respiratory Fluoroquinolones vs. Other Commonly Used Antimicrobials in Mild-to-Moderate Severity Community-Acquired Pneumonia
Keywords:Respiratory quinolones, quinolones, Community-acquired pneumonia, length of hospital stay, 30 days mortality, speed of recovery.
Respiratory Fluoroquinolones (RFQs) are widely used in the treatment of community-acquired pneumonia (CAP) in our part of the world. Our aim was to find if there was outcome difference between RFQ-based versus RFQ-exempt regimens.
A retrospective study of RFQs versus other commonly used antimicrobial therapy (OUAT) in the treatment of patients with mid-to-moderate CAP adjusted by pneumonia severity score (PSI). Rates of treatment outcome at end-of- therapy i.e. clinical improvement, length of hospital stay and speed of recovery were evaluated. Patients were included if they had Mild-to-Moderate severity CAP, â‰¥18 years old, completed â‰¥ 3 days of antimicrobials.
320 patients were included, mean age for all groups was 49.63 years (P = 0.204), males 60.3 % (P = 0.219). All had similar PSI score (Pearson X2 test = 13.75, P = 0.185). The first group (24.4%) is composed of RFQs monotherapy. The second group (50.6%) is composed of RFQs plus Î²-lactams. The third group (25%) is composed of OUAT. Diabetes was the most common comorbidity among all (P = 0.847). There was no significant difference among the three groups in clinical improvement (P = 0.424) and speed of recovery (P = 0.398), however length of hospital stay was significantly shorter for the RFQs monotherapy (P = 0.004)
Cumulative curve for probability of discharge did not show significant difference among the three therapy groups (P â‰¥ 0.20)
There were no significant difference among the groups regarding end-of-treatment clinical improvement rates, speed of recovery and probability of hospital discharge. However, they significantly differ in length of hospital stay for RFQs monotherapy (P = 0.004).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 3.0 License Â©
Copyright policies & self-archiving
This is our Copyright Policy. We are a RoMEO green journal.
|Author's Pre-print:||author can archive pre-print (ie pre-refereeing)|
|Author's Post-print:||author can archive post-print (ie final draft post-refereeing)|
|Publisher's Version/PDF:||author can archive publisher's version/PDF|